VRNA News and Press, Verona Pharma plc From 04/25/24

LONDON and RALEIGH, N.C., April 25, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for the first quarter ended March 31, 2024 on Thursday, May 9, 2024 and host an investme...

2024-04-15 14:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-03-31 21:35:02 ET More on Regeneron, Sanofi Regeneron's Triple Threat: Eylea, Libtayo, And Dupixent Dominate Sanofi: My Top Pick In Big Pharma Regeneron Pharmaceuticals, Inc. (REGN) Leerink Partners Global Biopharma Conference (Transcript) U.S. CDC warns...

LONDON and RALEIGH, N.C., March 04, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces Mr. Andrew Fisher has today joined the Company as General Counsel, and member of the Executive Management Team. Mr. Fisher ...

2024-03-01 08:45:00 ET Tech giant Nvidia has been one of the hottest stocks over the past couple of years, with its shares more than doubling since 2022. But technology isn't the only place where investors can find excellent investments. In fact, three healthcare stocks that h...

Evolv Technologies Holdings Inc. (EVLV) is expected to report $-0.14 for Q4 2023 The Lion Electric Company (LEV) is expected to report $-0.1 for Q4 2023 Fisker Inc. Class A (FSR) is expected to report $-0.2 for Q4 2023 Y-mAbs Therapeutics Inc. (YMAB) is expected to report $-0.19 for Q...

PDUFA Target Action Date for ensifentrine of June 26, 2024 Commercialization preparations advance Strong balance sheet supports commercialization and Company's growth Conference call today at 9:00 a.m. EST / 2:00 p.m. GMT LONDON and RALEIGH, N.C., Feb. 29, 2024 (GL...

2024-02-15 17:55:08 ET Summary VRNA's ensifentrine could be approved for the maintenance treatment of chronic obstructive pulmonary disease in June 2024. VRNA had $257M in cash at the end of Q3'23, and a debt facility worth up to $400M was set up in early 2024. While VRNA has ...

LONDON and RALEIGH, N.C., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for the fourth quarter and full year ended December 31, 2023 on Thursday, February 29, 20...

LONDON and RALEIGH, N.C., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”) announces Mr. Michael Austwick has today joined the board as a Non-Executive Director. Mr. Austwick brings a wealth of strategic and operational experience in the bio...